Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave

Meza, Daniel; Khuder, Basil; Bailey, Joseph; Rosenberg, Sharon R; Kalhan, Ravi; Reyfman, Paul A.

doi:10.2147/copd.s318000

Cited by 34 publications

(29 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, as they were characterized by both higher CCI and increased mortality rate. Such findings are consistent with other studies [ 40 , 41 ], which underlines the increased risks of negative outcomes in patients with COPD and COVID-19. Indeed, these patients received NIV more often, but invasive mechanical ventilation less frequently.…”

Section: Discussionsupporting

confidence: 93%

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

Nicola

Borrelli

Ridolfi

et al. 2022

JPM

View full text Add to dashboard Cite

Introduction: Asthma, along with inhaled steroids, was initially considered a risk factor for worse clinical outcomes in COVID-19. This was related to the higher morbidity observed in asthma patients during previous viral outbreaks. This retrospective study aimed at evaluating the prevalence of asthma among patients admitted due to SARS-CoV-2 infection as well as the impact of inhaled therapies on their outcomes. Furthermore, a comparison between patients with asthma, COPD and the general population was made. Methods: All COVID-19 inpatients were recruited between February and July 2020 from four large hospitals in Northwest Italy. Data concerning medical history, the Charlson Comorbidity Index (CCI) and the hospital stay, including length, drugs and COVID-19 complications (respiratory failure, lung involvement, and the need for respiratory support) were collected, as well as the type of discharge. Results: patients with asthma required high-flow oxygen therapy (33.3 vs. 14.3%, p = 0.001) and invasive mechanical ventilation (17.9 vs. 9.5%, p = 0.048) more frequently when compared to the general population, but no other difference was observed. Moreover, asthma patients were generally younger than patients with COPD (59.2 vs. 76.8 years, p < 0.001), they showed both a lower mortality rate (15.4 vs. 39.4%, p < 0.001) and a lower CCI (3.4 vs. 6.2, p < 0.001). Patients with asthma in regular therapy with ICS at home had significantly shorter hospital stay compared to those with no treatments (25.2 vs. 11.3 days, p = 0.024). Discussion: Our study showed that asthma is not associated with worse outcomes of COVID-19, despite the higher need for respiratory support compared with the general population, while the use of ICS allowed for a shorter hospital stay. In addition, the comparison of asthma with COPD patients confirmed the greater frailty of the latter, according to their multiple comorbidities.

show abstract

Section: Discussionsupporting

confidence: 93%

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

Nicola

Borrelli

Ridolfi

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…Similar to our report, COVID-19 patients aged older than 60 years with underlying CVD can aggravate symptoms and result in death outcomes [26,27]. Although, in our study, there was no statistically significant relationship between the comorbid underlying disease with death outcome in COVID-9 patients with CVD, all mentioned diseases, separately, were reported as a risk factor to worsen the condition and lead to death in these patients [28][29][30][31][32]. Among demographical and clinical characteristics, male gender, elderly age, and fever are associated with a greater risk of development of acute respiratory syndrome, severe condition, and death [31,33].…”

Section: Discussionsupporting

confidence: 85%

Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease

Yaghubi

Shakoori

Nasiri

et al. 2022

jcbior

View full text Add to dashboard Cite

New emerging severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) primarily affects the lungs, but the virus may cause cardiovascular disease (CVD), and a history of CVD is usually associated with comorbidities, which could increase the severity of infections. In this study, we collected demographic and clinical characteristics data from 123 patients with a history of CVD, who were confirmed to have SARS-CoV-2 infection by polymerase chain reaction (PCR) test in Razi Hospital, Rasht, Iran, from March 2021 to June 2021. Chi-Square and Fisher's Exact test with a significance level of P less than 0.05 was performed. All statistical analysis was performed with SPSS software version 26.0. Among the studied patients, 99 patients were discharged and 24 of them died. 62 (50.4%) of the study population were female and 61 (49.6%) were male, and there is no significant association between gender and the outcome of patients (P = 0.159). The total mean age of patients was 68.35±12.41. Statistical analysis has represented a significant relation of death outcomes in CVD patients with age 60 years and older (P = 0.001), in comparison with patients younger than 60 years. In this present study, no significant relation between underlying disease and mortality rate was reported, but in COVID-19 patients with a history of CVD and age upper than 60 years, death outcome was more probable.

show abstract

“…Chronic Obstructive Pulmonary Disease (COPD) is thought to increase the severity and mortality of COVID‐19 pneumonia (Lippi & Henry, 2020 ; Wu et al, 2020 ). In the N3C database, the risk of death was two times higher in those with COPD (Meza et al, 2021 ). Early in the pandemic, it was reported that hypertension was very common comorbidity with COVID‐19 (Guan et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 patients with documented alcohol use disorder or alcohol‐related complications are more likely to be hospitalized and have higher all‐cause mortality

Bailey

Sayles

Campbell

et al. 2022

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

Background Coronavirus Disease 2019 (COVID‐19) has affected every country globally, with hundreds of millions of people infected with the SARS‐CoV‐2 virus and over 6 million deaths to date. It is unknown how alcohol use disorder (AUD) affects the severity and mortality of COVID‐19. AUD is known to increase the severity and mortality of bacterial pneumonia and the risk of developing acute respiratory distress syndrome. Our objective is to determine whether individuals with AUD have increased severity and mortality from COVID‐19. Methods We utilized a retrospective cohort study of inpatients and outpatients from 44 centers participating in the National COVID Cohort Collaborative. All were adult COVID‐19 patients with and without documented AUDs. Results We identified 25,583 COVID‐19 patients with an AUD and 1,309,445 without. In unadjusted comparisons, those with AUD had higher odds of hospitalization (odds ratio [OR] 2.00, 95% confidence interval [CI] 1.94 to 2.06, p < 0.001). After adjustment for age, sex, race/ethnicity, smoking, body mass index, and comorbidities, individuals with an AUD still had higher odds of requiring hospitalization (adjusted OR [aOR] 1.51, CI 1.46 to 1.56, p < 0.001). In unadjusted comparisons, individuals with AUD had higher odds of all‐cause mortality (OR 2.18, CI 2.05 to 2.31, p < 0.001). After adjustment as above, individuals with an AUD still had higher odds of all‐cause mortality (aOR 1.55, CI 1.46 to 1.65, p < 0.001). Conclusion This work suggests that AUD can increase the severity and mortality of COVID‐19 infection. This reinforces the need for clinicians to obtain an accurate alcohol history from patients hospitalized with COVID‐19. For this study, our results are limited by an inability to quantify the daily drinking habits of the participants. Studies are needed to determine the mechanisms by which AUD increases the severity and mortality of COVID‐19.

show abstract

Mortality from COVID-19 in Patients with COPD: A US Study in the N3C Data Enclave

Cited by 34 publications

References 8 publications

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy

Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease

COVID‐19 patients with documented alcohol use disorder or alcohol‐related complications are more likely to be hospitalized and have higher all‐cause mortality

Contact Info

Product

Resources

About